Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 700 Us Highway 202/206 BRIDGEWATER NJ 08807 |
Tel: | 1-718-5945332 |
Website: | https://insmed.com |
IR: | See website |
Key People | ||
William H. Lewis Chairman of the Board, President, Chief Executive Officer | Sara M. Bonstein Chief Financial Officer | Roger Adsett Chief Operating Officer |
S. Nicole Schaeffer Chief People Strategy Officer | Michael A. Smith Senior Vice President, General Counsel, Corporate Secretary | Martina Flammer Chief Medical Officer | Drayton Wise Chief Commercial Officer |
Business Overview |
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). |
Financial Overview |
For the fiscal year ended 31 December 2023, Insmed Inc revenues increased 24% to $305.2M. Net loss increased 56% to $749.6M. Revenues reflect US segment increase of 21% to $224.2M, Europe and rest of worldld segment increase from $2.9M to $15.3M. Higher net loss reflects Other Non Operating I/E increase from $20.8M (income) to $28.7M (expense), Term Loan contractual interest expense increase from $8.3M to $46.7M (expense). |
Employees: | 912 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,158M as of Dec 31, 2023 |
Annual revenue (TTM): | $305.21M as of Dec 31, 2023 |
EBITDA (TTM): | -$667.64M as of Dec 31, 2023 |
Net annual income (TTM): | -$749.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$549.54M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $404.50M as of Dec 31, 2023 |
Shares outstanding: | 148,555,217 as of Mar 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |